Detalles de la búsqueda
1.
Engineering a bispecific antibody with a common light chain: Identification and optimization of an anti-CD3 epsilon and anti-GPC3 bispecific antibody, ERY974.
Methods
; 154: 10-20, 2019 02 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-30326272
2.
Engineering CD3/CD137 dual specificity into a DLL3-targeted T-cell engager enhances T-cell infiltration and efficacy against small cell lung cancer.
Cancer Immunol Res
; 2024 Mar 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-38558120
3.
Engineering CD3/CD137 Dual Specificity into a DLL3-Targeted T-Cell Engager Enhances T-Cell Infiltration and Efficacy against Small-Cell Lung Cancer.
Cancer Immunol Res
; : OF1-OF12, 2024 Apr 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-38563577
4.
Antibody to CD137 Activated by Extracellular Adenosine Triphosphate Is Tumor Selective and Broadly Effective In Vivo without Systemic Immune Activation.
Cancer Discov
; 11(1): 158-175, 2021 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-32847940
5.
Trierixin, a novel Inhibitor of ER stress-induced XBP1 activation from Streptomyces sp. 1. Taxonomy, fermentation, isolation and biological activities.
J Antibiot (Tokyo)
; 60(9): 547-53, 2007 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-17917237
6.
Trierixin, a novel Inhibitor of ER stress-induced XBP1 activation from Streptomyces sp. II. structure elucidation.
J Antibiot (Tokyo)
; 60(9): 582-5, 2007 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-17917242
7.
Engineered monoclonal antibody with novel antigen-sweeping activity in vivo.
PLoS One
; 8(5): e63236, 2013.
Artículo
en Inglés
| MEDLINE | ID: mdl-23667591
Resultados
1 -
7
de 7
1
Próxima >
>>